In recent years, the entire precision medical industry is undergoing tremendous changes. In addition to the wider acceptance of the concept of genetic testing, the accompanying diagnostic market, which was originally dominated by small panels, has also begun to transform into a large panel. Therefore, the acquisition of more comprehensive information for clinical treatment through the large pane cancer gene test has become the main development direction of the current precision medical industry .
“In particular, in the field of cancer and oncology, precision medicine can avoid the original “sprinkle pepper†treatment and provide patients with more accurate and personalized medical services.†Recently, Director of Center for Medical Management and Policy Research, China Europe International Business School Professor Jiangnan said this in the second session of the source to the China-US Summit Forum. He also believes that how to solve the problem of lack of medical resources and make precision medicine truly go from research to clinical is also an important issue in the precision medical industry.
Individualized precision treatment
Since the end of last year, FMI's F1CDx has become the world's first approved large panel product. Then, the US National Health Insurance CMS achieved medical insurance coverage for the large panel cancer gene test. These two milestones clearly confirmed that the US regulatory authorities have the greatest recognition of the necessity of large panel as a diagnostic and treatment for tumor therapy.
Through the large panel cancer gene detection products, doctors can understand the causes of cancer development and even have a more comprehensive understanding of the molecular mechanisms of drug resistance. As a result, doctors can avoid wasting valuable samples to the greatest extent, and patients can avoid missed opportunities for early screening and early treatment to meet clinically accurate personalized medical needs.
Since cancer itself is a genetic disease, each cancer has a unique genetic mutation. According to Wang Kai, CEO of the medical treatment, precision treatment is the frontier and hot spot of cancer research. Accurate detection is the premise of precision treatment.
Based on this understanding, Zhiben Medical currently uses the second-generation sequencing technology and the original black technology, combined with clinical annotations, to provide comprehensive detection of 450 cancer genes, in order to achieve accurate detection. In addition, the clinical testing service network to the medical service has covered more than 200 core hospitals in nearly 40 key cities across the country.
Precision medicine is no longer exclusive to "rich people"
This year, the US Food and Drug Administration has included more than 300 cancer genetic testing products in the US, which means that the treatment of cancer will usher in change.
In addition, Qin Ying, a medical COO, believes that this incident actually proves that precision medicine is no longer exclusive to “rich people.†In the future, precision medicine will become the basic right that all patients should have.
Professor Cai Jiangnan also advocated at the conference to make spoiler innovation in the field of medical health. He explained that medical services need to provide patients with cost-effective and accessible medical services, which requires them to reduce the cost of medical services while providing easier and better quality medical services in terms of technology and models.
Whether it is to avoid the waste of medical resources, or early screening for early treatment compared to advanced treatment, large panel cancer genetic testing products and doctors and patients have greatly reduced medical costs. Cai Jiangnan believes that precision medicine actually gave up the original "sprinkle pepper" treatment, and turned to more accurate methods to find the cause and treatment method, which is very consistent with the connotation of spoiler innovation.
Starting with technical barriers, focusing on clinical
However, the current domestic precision medical market is still in the trial stage. Compared with the Chinese patient population, the detection rate of the large panel is still low. At the conference, Professor Cai Jiangnan attributed this phenomenon to the lack of clinical research in domestic medical institutions. He believes that preclinical research is important, but the final step in medical innovation is the need to go to the clinic. In the absence of high-quality doctor resources, China is still extremely lacking in research on clinical data.
Recently, the state has continuously increased efforts to encourage new drug research and development and accelerate the launch of new drugs. The domestic oncology drug research and development market is also in urgent need of enterprises that can truly provide reliable data and value analysis. In this regard, Professor Wu Yilong, the lifelong director of the People's Hospital of Guangzhou, said that in 2018, China's first immune checkpoint inhibitor will be launched soon. China's immunotherapy needs to speed up clinical trials and select the best biomarkers through accurate detection. Make precision treatments more effective for more patients.
At this summit, Zhiben Medical announced a number of new findings on the Chinese cancer patients first reported internationally. These data combined with clinical examples will bring practical and effective applications for clinical treatment. In addition, the medical technology has also announced a number of international clinical research platforms.
As for the medical COO Qin Ying told Yiou to be healthy, the medical treatment will not only establish technical barriers, but focus on the actual products that turn technology into clinical benefits. Based on this concept, Zhiben Medical believes that big data is one of the keys to realizing this. By continuously collecting accurate and comprehensive genetic data and clinical treatment information, a database for the Chinese population will be established.
Ventilation is one of the most important components in a successful greenhouse.
If there is no proper ventilation, greenhouses and their growing plants can become prone to problems. The main purposes of ventilation are to regulate the temperature and humidity to the optimal level, and to ensure movement of air and thus prevent build-up of plant pathogens (such as Botrytis cinerea) that prefer still air conditions. Ventilation also ensures a supply of fresh air for photosynthesis and plant respiration, and may enable important pollinators to access the greenhouse crop.
Greenhouse Circulation Fan,Greenhouse Ventilation Fan,Automated Greenhouse Ventilation Fan
JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.spgreenhouse.com